Dr. Melinda Sue Dunlap, MD

Dr. Dunlap practices at Oklahoma Cancer Specialists and Research Institute in Tulsa, Oklahoma.

Dr. Dunlap's NPI, 1609096668, was assigned on May 1, 2007. Dr. Dunlap graduated from University of Arkansas College of Medicine in 2004. Dr. Dunlap holds Oklahoma license 28469.

Dr. Dunlap's primary practice is Oklahoma Cancer Specialists and Research Institute, at 12697 E 51st S St, Tulsa, OK 74146 in Tulsa County. The practice phone is (918) 505-3200.

Dr. Dunlap's primary practice is Oklahoma Cancer Specialists and Research Institute in Tulsa, Oklahoma. Dr. Dunlap is also affiliated with Saint Francis Hospital. The medical group on file is Oklahoma Cancer Specialists and Research Institute. Dmand AI also links Dr. Dunlap to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dunlap practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dunlap's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Dunlap's licenses on file in 3 states: Oklahoma, Pennsylvania and Texas.

CMS data shows 132,126 Medicare services from Dr. Dunlap across 81 procedure codes in 2024, for 1,056 Medicare patients. Medicare paid $1,697,778 for them.

CMS counts 1,056 Medicare patients who saw Dr. Dunlap in 2024. The largest group is 65 to 74, with 461 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.27, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dunlap's median patient age at 71, with 73% women.

In 2024, Dr. Dunlap wrote 2,572 Medicare Part D claims for 371 patients. 83% of them were for generic drugs. CMS names the drug for 2,311 of them, across 55 drugs with 11 or more claims each, at $3,923,448 in total drug cost. In 2023, CMS named 2,353 claims across 48 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Dunlap for performance year 2024, reported individually. Dr. Dunlap accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Dunlap in 2023.

Dmand AI links Dr. Dunlap to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Breast Neoplasms and Breast Diseases.

CMS Open Payments shows 126 general payments to Dr. Dunlap from 35 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 88% of the total. AstraZeneca Pharmaceuticals LP paid the most, $556.

Dr. Dunlap graduated from University of Arkansas College of Medicine in 2004.